Etanercept, a soluble tumor necrosis factor receptor, palliates constitutional symptoms in patients with myelofibrosis with myeloid metaplasia: Results of a pilot study

Blood

Volumn 99, Issue 6, 2002, Pages 2252-2254

  Steensma, David P ^a,b   Mesa, Ruben A ^a,b   Li, Chin Yang ^a,b   Gray, Leigh ^a,b   Tefferi, Ayalew ^a,b  

^a Division of Hematology   (United States)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ETANERCEPT; TUMOR NECROSIS FACTOR RECEPTOR;

ADULT; AGED; ARTICLE; CELL COMPOSITION; CLINICAL ARTICLE; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; FEMALE; HUMAN; HUMAN TISSUE; INJECTION SITE; MALE; MYELOFIBROSIS; MYELOID METAPLASIA; PALLIATIVE THERAPY; PANCYTOPENIA; PILOT STUDY; PRIORITY JOURNAL; SYMPTOMATOLOGY;

EID: 0037085756     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V99.6.2252     Document Type: Article

References (7)

1. Myelofibrosis with myeloid metaplasia
2. Bone marrow histochemical studies of fibrogenic cytokines and their receptors in myelodysplastic syndrome with myelofibrosis and related disorders
3. Tumor necrosis factor (TNF)-alpha directly inhibits human erythropoiesis in vitro: Role of p55 and p75 TNF receptors
4. Interferon-gamma and tumor necrosis factor-alpha suppress both early and late stages of hematopoiesis and induce programmed cell death
5. TNF-alpha stimulation of fibroblast proliferation. Dependence on platelet-derived growth factor (PDGF) secretion and alteration of PDGF receptor expression
6. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1
7. The syndrome of anorexia-cachexia